US EditionFDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market
Lilly said the once-daily pill will cost $149 for cash-paying patients at the lowest dose and could reach Medicare patients this summer.
- On Wednesday, April 1, 2026, the U.S. Food and Drug Administration approved Eli Lilly and Company's Foundayo , a once-daily oral GLP-1 pill for chronic weight management in adults with obesity or weight-related medical problems.
- The agency granted this approval in 50 days under its National Priority Voucher program, the fastest new molecular entity clearance since 2002, following Lilly's 2018 licensing of the molecule from Japan's Chugai Pharmaceutical Co., Ltd.
- Clinical trial data from the ATTAIN-1 program showed participants on the highest dose lost an average of 12.4% of body weight over 72 weeks; the pill offers flexibility as it lacks food or water restrictions.
- Lilly will begin direct shipments via its LillyDirect platform on April 6, with pricing starting at $149 for self-pay patients; eligible Medicare Part D beneficiaries may access the pill for $50 beginning July 1.
- Competition with Novo Nordisk's Wegovy pill intensifies as drugmakers race to capture the expanding non-injectable GLP-1 market, positioning Lilly's oral option to extend access beyond current injectable treatments for obesity management.
145 Articles
145 Articles
Lilly's Oral Obesity Drug Also Receives FDA Approval; War on Oral Obesity Treatments Heats Up in Earnest. The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's oral medication for obesity treatment. With this approval, the battle for dominance in the global obesity treatment market has entered its second round in earnest. ◇ Lilly's Oral Obesity Drug Foundayot Wins FDA Approval
US approves new Eli Lilly GLP-1 pill
US regulators on Wednesday approved Eli Lilly’s GLP-1 pill for sale in the country, opening up a new phase in weight-loss medication. The drug, which will be sold under the brand name Foundayo, will compete with the pill version of Novo Nordisk’s Wegovy, approved in December. But Lilly’s pill is cheaper to manufacture and more convenient to consume, Vox noted. It is similar in form to statins or blood-pressure medications — unlike Wegovy’s, whic…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
